[Histonet] RE: therapeutic antibody detection in mouse--Histonet Digest, Vol 60, Issue 33

[Nerissa Mendoza]

Sam,

Isn't Herceptin a humanized mAb?  I believe you need to detect it with
an anti-human antibody (rather than mouse)?

Nerissa Mendoza
Senior Research Associate I
Preclinical Research & Development
 
XOMA (US) LLC
2910 Seventh Street
Berkeley, CA 94710

------------------------------

Message: 3
Date: Wed, 19 Nov 2008 14:22:57 -0500
From: "Perry, Samuel" <Samuel_Perry <@t> DFCI.HARVARD.EDU>
Subject: [Histonet] therapeutic antibody detection in mouse
	xenografts?
To: <histonet <@t> lists.utsouthwestern.edu>
Message-ID:
	<D3C984272CCAA741879C0B9339D1A76779BA7B <@t> PHSXMB24.partners.org>
Content-Type: text/plain; charset="us-ascii"

Hi All,
I am wondering if anyone has experience showing therapeutic monoclonal
antibody binding in mouse xenografts (human tumor cells injected
subcutaneously in SCID mice and then dose treated with therapeutic
antibody injected intraperitoneally).  For instance, can trastuzamab
(Herceptin) binding be seen in a breast tumor xenograft treated with
Herceptin?  I have tried using Dako's goat-anti mouse dextran HRP
conjugated secondary antibody developed with DAB.  I also tried using an
Abcam goat-anti mouse antibody conjugated with biotin, then adding
Vectors elite ABC, then developing with DAB.  Both times I used FFPE
tissue.  In both techniques, results showed minimal to staining and
showed no difference between mice treated with antibody and control mice
treated.  I would appreciate if anyone knew of published papers or have
experience using IHC to show therapeutic antibody bound to tumor cell in
mouse xenografts. 
Thanks -Sam 

Research Technician
Dana Farber Cancer Institute
Boston MA.

The information transmitted in this electronic communication is intended
only for the person or entity to whom it is addressed and may contain
confidential and/or privileged material. Any review, retransmission,
dissemination or other use of or taking of any action in reliance upon
this information by persons or entities other than the intended
recipient is prohibited. If you received this information in error,
please contact the Compliance HelpLine at 800-856-1983 and properly
dispose of this information.



-- 
The information contained in this email message may 
contain confidential or legally privileged information and is intended solely 
for the use of the named recipient(s).  No confidentiality or privilege is 
waived or lost by any transmission error. If the reader of this message is 
not the intended recipient, please immediately delete the e-mail and all 
copies of it from your system, destroy any hard copies of it and notify the 
sender either by telephone or return e-mail.  Any direct or indirect use, 
disclosure, distribution, printing, or copying of any part of this message is 
prohibited.  Any views expressed in this message are those of the individual 
sender, except where the message states otherwise and the sender is 
authorized to state them to be the views of XOMA.